Clinical trial
Eribulin Mesylate and Cisplatin in Treating Patients With Advanced Solid Tumors
NCT00415324 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00415324 |
|---|---|
| Title | Eribulin Mesylate and Cisplatin in Treating Patients With Advanced Solid Tumors |
| Official title | A Phase 1 Study of Halichondrin B Analog (E7389) in Combination With Cisplatin in Advanced Solid Tumors |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug, Other |
| Interventions | eribulin mesylate, cisplatin, laboratory biomarker analysis, pharmacological study |
| Enrollment | 36 |
| Start date | Dec 1, 2006 |
| Primary completion | May 1, 2014 |
| First posted | Dec 22, 2006 |
| Last update posted | May 20, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: